Wang X-Y, Qin Y-Y
Pharmaceutical compounding of AOD-9604 is legal if done under proper licensing, but claims of efficacy for weight loss or disease treatment would constitute illegal drug marketing
Originally developed for facial fat loss, Sculptra is an ideal choice for patients who notice facial thinning from GLP-1 medications such as semaglutide or tirzepatide
The triple-agonist hypothesis predicts that GIP receptor activation, by enhancing insulin secretion and improving glycemic control, will offset the hyperglycemic effects of glucagon receptor activation while preserving its energy-expenditure benefits
Mori N, Oda K, Takakura H, Tanaka Y, Yokooji T, Murakami T
Figure 2 3 Evidence from human studies The first results relating to the synergistic effect of GIP and GLP-1RAs on humans came from small sample size studies in which the synergistic effect of an infusion of both molecules during an oral glucose tolerance test (OGTT) on insulin levels and glucose tolerance was observed